Roche’s blockbuster idiopathic pulmonary fibrosis drug Esbriet brings in more than $1 billion a year — and the Swiss pharma giant would like to keep it that way. Too bad a Delaware federal judge doesn’t agree.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,